Please provide your email address to receive an email when new articles are posted on . Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among ...
The study included 1032 patients: 658 denosumab users and 374 oral bisphosphonate users. HealthDay News — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a ...
LOS ANGELES, Dec 14 (Reuters) - Amgen Inc said on Friday that osteoporosis drug denosumab, the biotechnology company's most important new offering, increased bone strength in women receiving hormone ...
LOS ANGELES, May 28 (Reuters) - Amgen Inc said on Wednesday its experimental osteoporosis drug denosumab achieved greater bone density than Merck & Co Inc's Fosamax, but some analysts expressed ...
THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience ...
Please provide your email address to receive an email when new articles are posted on . Samsung Bioepis received approval for two biosimilars of denosumab that are interchangeable with Prolia and ...
Stoboclo and Osenvelt, biosimilars of Prolia and Xgeva, are approved for various cancer-related bone conditions, offering cost-effective alternatives. FDA approval confirms therapeutic equivalence of ...
Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related conditions. The Patels added, "With the addition of two denosumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results